Drug search by name

Moxetumomab pasudotox and Hemolytic uremic syndrome

Result of checking the interaction of drug Moxetumomab pasudotox and disease Hemolytic uremic syndrome for safety when used together.

Check result:

Moxetumomab pasudotox <> Hemolytic uremic syndrome

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Hemolytic Uremic Syndrome (HUS), including life threatening cases, has been reported in patients treated with moxetumomab pasudotox, and is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and progressive renal failure. Avoid moxetumomab pasudotox in patients with prior history of severe thrombotic microangiopathy (TMA) or HUS. Monitor blood chemistry and complete blood counts prior to each dose and on Day 8 of each treatment cycle. Monitoring mid- cycle is also recommended. Consider the diagnosis of HUS in patients who develop hemolytic anemia, worsening or sudden onset of thrombocytopenia, increase in creatinine levels, elevation of bilirubin and/or LDH, and have evidence of hemolysis based on peripheral blood smear schistocytes. The events of HUS may be life-threatening if treatment is delayed with increased risk of progressive renal failure requiring dialysis. If HUS is suspected initiate appropriate supportive measures, including fluid repletion, hemodynamic monitoring, and consider hospitalization as clinically indicated. Discontinue treatment with moxetumomab pasudotox in patients with HUS.

Moxetumomab pasudotox

Generic Name: moxetumomab pasudotox

Brand Name: Lumoxiti

Synonyms: Moxetumomab Pasudotox

What is Moxetumomab pasudotox?